Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,059,562.50 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 18,750 shares of Akero Therapeutics stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $56.51, for a total transaction of $1,059,562.50. Following the completion of the sale, the insider now owns 170,237 shares of the company’s stock, valued at $9,620,092.87. This trade represents a 9.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Timothy Rolph also recently made the following trade(s):

• On Monday, January 27th, Timothy Rolph sold 31,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $55.77, for a total value of $1,742,812.50.
• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.91, for a total value of $148,924.38.

Akero Therapeutics Trading Down 1.3 %

NASDAQ:AKRO opened at $54.21 on Friday. Akero Therapeutics, Inc. has a 52 week low of $17.84 and a 52 week high of $58.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The firm’s fifty day moving average is $32.60 and its 200-day moving average is $29.85. The firm has a market cap of $3.78 billion, a P/E ratio of -14.46 and a beta of -0.11.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Equities analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AKRO. Mirae Asset Global Investments Co. Ltd. grew its stake in Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after purchasing an additional 446 shares during the period. Handelsbanken Fonder AB boosted its holdings in shares of Akero Therapeutics by 5.0% during the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company’s stock worth $584,000 after buying an additional 1,000 shares in the last quarter. Rhumbline Advisers grew its position in shares of Akero Therapeutics by 1.3% during the 4th quarter. Rhumbline Advisers now owns 105,686 shares of the company’s stock worth $2,940,000 after buying an additional 1,310 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Akero Therapeutics by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company’s stock valued at $412,000 after acquiring an additional 1,446 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd lifted its position in shares of Akero Therapeutics by 13.8% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company’s stock valued at $485,000 after acquiring an additional 2,049 shares during the period.

Analysts Set New Price Targets

Several research firms recently issued reports on AKRO. Morgan Stanley increased their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $35.00 to $63.00 in a report on Thursday, January 30th. UBS Group boosted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Citigroup raised their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Finally, HC Wainwright lifted their target price on Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, Akero Therapeutics has a consensus rating of “Buy” and a consensus target price of $75.86.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.